Prelude Therapeutics grants 25,000 stock options to Interim CFO Bryant D. Lim

Prelude Therapeutics Inc

Options to purchase 25,000 shares of common stock at $3.86 per share.
Options vest over 4 years (25% at 1 year, then monthly); 10-year term.
Grant approved by Compensation Committee on May 14, 2024, under 2020 Equity Incentive Plan.
Amendment to prior 8-K reporting Lim's appointment as Interim CFO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.